IntegriChain, the leading channel management cloud used by life sciences suppliers has received a strategic equity investment from Accel-KKR, a technology-focused investment firm with $4.0 billion in capital commitments to its current funds. Under the terms of the investment, Accel-KKR will acquire 100% of the equity not held by members of IntegriChain's management team. Needham & Company acted as the exclusive financial advisor to IntegriChain.
IntegriChain is the leading channel management cloud used by life sciences suppliers, including nine of the top 10 pharmaceutical manufacturers, to drive channel collaboration and to improve the efficiency of how products reach customers. Pharmaceutical, biopharm/specialty pharma, generics, and consumer health suppliers use IntegriChain to manage their supply chain relationships, inventories, and orders across a vast network of retailers, ecommerce, and distributors. As a suite of informed applications and analytics built on top of aggregated channel inventory and point-of-sale (POS) data, IntegriChain provides customer operations, national accounts, and finance teams with a collaborative, agile, and mobile alternative to ERP and homegrown systems. By embedding big-data customer insights into daily business processes, IntegriChain helps control the high cost of product distribution while improving product availability, ensuring a higher level of revenue predictability and maximizing distribution investment. More than $200 billion in annual U.S. commerce and 2 billion transactions flow through the IntegriChain Cloud annually. IntegriChain is backed by Accel-KKR, a leading technology private equity firm.